Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearBased onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerDuration of timepatients willtakeabemaciclib inearly stagediseaseThe onlysteroidalaromataseinhibitor in itsdrug classPatients withHER2+ diseasecontinuetargetedtherapy for thisduration1%This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This drugclass are thebackbone ofHR+ diseaseThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Used asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredregimen forHR+ diseasefor frail/elderlypatientsPreferredfrequencyof GnRHagonistsThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This treatmentmodality isalwayscombined withlumpectomysurgeryThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agentshould beinitiated withneratinib for thefirst 8 weeksThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearBased onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerDuration of timepatients willtakeabemaciclib inearly stagediseaseThe onlysteroidalaromataseinhibitor in itsdrug classPatients withHER2+ diseasecontinuetargetedtherapy for thisduration1%This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This drugclass are thebackbone ofHR+ diseaseThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Used asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredregimen forHR+ diseasefor frail/elderlypatientsPreferredfrequencyof GnRHagonistsThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This treatmentmodality isalwayscombined withlumpectomysurgeryThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agentshould beinitiated withneratinib for thefirst 8 weeksThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapy

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  2. This agent can be added to LN+ HER2+ disease given with trastuzumab
  3. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  4. Based on Oncotype DX, a score of 35 will receive this treatment
  5. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  6. Duration of time patients will take abemaciclib in early stage disease
  7. The only steroidal aromatase inhibitor in its drug class
  8. Patients with HER2+ disease continue targeted therapy for this duration
  9. 1%
  10. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  11. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  12. This drug class are the backbone of HR+ disease
  13. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  14. This agent can cause endometrial cancer, but has bone density protective effect
  15. This should be monitored routinely every 3-4 months while receiving trastuzumab
  16. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  17. Preferred regimen for HR+ disease for frail/elderly patients
  18. Preferred frequency of GnRH agonists
  19. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  20. This treatment modality is always combined with lumpectomy surgery
  21. This subtype of breast cancer has the lowest relative 5-year survival rate
  22. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  23. This agent should be initiated with neratinib for the first 8 weeks
  24. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy